Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CNTAVery BullishM&Anews

High materiality9/10

Eli Lilly to acquire Centessa Pharmaceuticals in strategic deal

Mar 31, 2026, 6:47 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The acquisition at a substantial premium signifies strong market confidence and potential growth in Centessa's asset value, similar to past biotechnology M&As which resulted in price surges upon announcements.

AI summary

What happened, with direct paths to the underlying reporting

Eli Lilly has announced its acquisition of Centessa Pharmaceuticals for $38 per share, which could reach $47 with contingent value rights tied to regulatory milestones. This acquisition enhances Lilly's neuroscience and sleep disorder portfolio, solidifying its commitment to innovative therapies in the field. The deal is expected to close in Q3 2026, subject to approvals.

Lilly to acquire Centessa Pharmaceuticals for $38 per share.
Centessa specializes in sleep-wake disorder therapeutics with promising pipeline.
Total potential value per share could reach $47 with milestone payments.
Transaction expected to close in Q3 2026, pending shareholder approval.
Acquisition expands Lilly's capabilities in neuroscience and sleep medicine.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Eli Lilly to acquire Centessa Pharmaceuticals in strategic deal

Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3 Billion